消化肿瘤杂志-官方网站
过刊浏览

过刊浏览

onlinebrowsing

T细胞免疫球蛋白黏蛋白3 在结直肠癌中的研究进展

Research progress on T-cell immunoglobulin mucin 3 in colorectal cancer

发布日期:2023-10-28 11:38:09 阅读次数: 0 下载

 

作者:陆正闵,尚学琴


单位:云南大学附属医院 肿瘤科,云南 昆明 650021

 

Authors:  Lu Zhengmin, Shang Xueqin

 

Unit:  Department of Oncology, Yunnan University Affiliated Hospital, Kunming 650021, Yunnan, China

 

摘要:

T 细胞免疫球蛋白黏蛋白3T-cell immunoglobulin mucin 3 TIM-3)是近年来被广泛研究的免疫调节蛋白,它在肿瘤的免疫治疗中具有重要的意义。TIM-3是属于TIM家族的Ⅰ型跨膜蛋白,其在多种免疫细胞和非免疫细胞中均有表达。TIM-3在机体免疫反应过程中起到负调节的作用,TIM-3与配体相互作用后可诱导T细胞凋亡,从而能够抑制免疫细胞的活性, 使肿瘤细胞能够逃避免疫系统的攻击。TIM-3已成为了肿瘤免疫治疗的一个关键靶点,联合阻断TIM-3和其他免疫检查点分子,可以增强T细胞的杀伤能力,进一步提高抗癌治疗的效果。本文就TIM-3与结直肠癌的发生发展、临床病理特征、预后及免疫治疗等的相关研究作一综述,探讨TIM-3作为结直肠癌免疫治疗靶点的重要地位及其临床价值。

 

关键词: 结直肠癌;T 细胞免疫球蛋白黏蛋白3;免疫逃逸;临床病理特征;预后;免疫治疗;综述

 

Abstract

T-cell immunoglobulin mucin 3 (TIM-3) is an extensively studied immune regulatory protein in recent years and plays a crucial role in immunotherapy against cancer. TIM-3 is a type I transmembrane protein that belongs to the TIM family, and it is expressed in various immune and non-immune cells. Research has indicated that TIM-3 exerts negative regulation in the immune response of the body. The interaction between TIM-3 and its ligand can induce T-cell apoptosis, thus inhibiting the activity of immune cells and enabling cancer cells to evade immune attacks. TIM-3 has become a key target in cancer immunotherapy. By blocking TIM-3 in combination with other immune checkpoint molecules, the cytotoxicity of T-cells can be enhanced and further improve the effectiveness of the anti-cancer therapy. This review summarizes the research on the relationship between TIM-3 and colorectal cancer, including the occurrence and development of colorectal cancer, clinical pathological features, prognosis, and immune therapy. The review discusses the important role of TIM-3 as a therapeutic target for colorectal cancer immune therapy and its clinical significance.

 

Key Words:  Colorectal cancer; T-cell immunoglobulin mucin 3; Immune evasion; Clinical pathological features; Prognosis; Immune therapy; Review

 

上一篇:暂无上一篇

下一篇:暂无下一篇

友情链接
中国科学文献服务系统 中国期刊全文数据库 美国生物医学信息检索系统
E-mail
digestiveoncology@163.com
联系电话
020-87616240
编辑部地址
地址:广州越秀区中山二路58号5号楼19楼胃肠外科中心

关注我们

粤ICP备10090623号 技术支持:中网科技